These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 30806568)

  • 1. Nanoparticle systems for cancer vaccine.
    Wen R; Umeano AC; Kou Y; Xu J; Farooqi AA
    Nanomedicine (Lond); 2019 Mar; 14(5):627-648. PubMed ID: 30806568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The quest for nanoparticle-powered vaccines in cancer immunotherapy.
    Sun Z; Zhao H; Ma L; Shi Y; Ji M; Sun X; Ma D; Zhou W; Huang T; Zhang D
    J Nanobiotechnology; 2024 Feb; 22(1):61. PubMed ID: 38355548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoparticle drug delivery systems: an excellent carrier for tumor peptide vaccines.
    Wang J; Hu X; Xiang D
    Drug Deliv; 2018 Nov; 25(1):1319-1327. PubMed ID: 29869539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineered Nanoparticles for Cancer Vaccination and Immunotherapy.
    Aikins ME; Xu C; Moon JJ
    Acc Chem Res; 2020 Oct; 53(10):2094-2105. PubMed ID: 33017150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanovaccine: an emerging strategy.
    Das A; Ali N
    Expert Rev Vaccines; 2021 Oct; 20(10):1273-1290. PubMed ID: 34550859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer Vaccines Designed Based the Nanoparticle and Tumor Cells for the Treatment of Tumors: A Perspective.
    Wu QJ; Lv WL
    IET Nanobiotechnol; 2024; 2024():5593879. PubMed ID: 38863969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunostimulatory colloidal delivery systems for cancer vaccines.
    Saupe A; McBurney W; Rades T; Hook S
    Expert Opin Drug Deliv; 2006 May; 3(3):345-54. PubMed ID: 16640495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Visible Codelivery Nanovaccine of Antigen and Adjuvant with Self-Carrier for Cancer Immunotherapy.
    Dong X; Liang J; Yang A; Qian Z; Kong D; Lv F
    ACS Appl Mater Interfaces; 2019 Feb; 11(5):4876-4888. PubMed ID: 30628437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymer nanotechnology based approaches in mucosal vaccine delivery: challenges and opportunities.
    Sharma R; Agrawal U; Mody N; Vyas SP
    Biotechnol Adv; 2015; 33(1):64-79. PubMed ID: 25499178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient Nanovaccine Delivery in Cancer Immunotherapy.
    Zhu G; Zhang F; Ni Q; Niu G; Chen X
    ACS Nano; 2017 Mar; 11(3):2387-2392. PubMed ID: 28277646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Cancer Nanovaccine for Co-Delivery of Peptide Neoantigens and Optimized Combinations of STING and TLR4 Agonists.
    Baljon JJ; Kwiatkowski AJ; Pagendarm HM; Stone PT; Kumar A; Bharti V; Schulman JA; Becker KW; Roth EW; Christov PP; Joyce S; Wilson JT
    ACS Nano; 2024 Mar; 18(9):6845-6862. PubMed ID: 38386282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rational Design of T-Cell- and B-Cell-Based Therapeutic Cancer Vaccines.
    Li WH; Su JY; Li YM
    Acc Chem Res; 2022 Sep; 55(18):2660-2671. PubMed ID: 36048514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging advances in synthetic cancer nano-vaccines: opportunities and challenges.
    Ahmad MZ; Ahmad J; Haque A; Alasmary MY; Abdel-Wahab BA; Akhter S
    Expert Rev Vaccines; 2020 Nov; 19(11):1053-1071. PubMed ID: 33315512
    [No Abstract]   [Full Text] [Related]  

  • 14. Lipid- and Polymer-Based Nanocarrier Platforms for Cancer Vaccine Delivery.
    Sunoqrot S; Abdel Gaber SA; Abujaber R; Al-Majawleh M; Talhouni S
    ACS Appl Bio Mater; 2024 Aug; 7(8):4998-5019. PubMed ID: 38236081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccine-like nanomedicine for cancer immunotherapy.
    Yi Y; Yu M; Li W; Zhu D; Mei L; Ou M
    J Control Release; 2023 Mar; 355():760-778. PubMed ID: 36822241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanoparticle delivery systems in cancer vaccines.
    Krishnamachari Y; Geary SM; Lemke CD; Salem AK
    Pharm Res; 2011 Feb; 28(2):215-36. PubMed ID: 20721603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Particulate carrier systems as adjuvants for cancer vaccines.
    Saung MT; Ke X; Howard GP; Zheng L; Mao HQ
    Biomater Sci; 2019 Nov; 7(12):4873-4887. PubMed ID: 31528923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potential of nanoparticle vaccines as a treatment for cancer.
    Urbanavicius D; Alvarez T; Such GK; Johnston APR; Mintern JD
    Mol Immunol; 2018 Jun; 98():2-7. PubMed ID: 29395251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PLGA nanoparticle-mediated delivery of tumor antigenic peptides elicits effective immune responses.
    Ma W; Chen M; Kaushal S; McElroy M; Zhang Y; Ozkan C; Bouvet M; Kruse C; Grotjahn D; Ichim T; Minev B
    Int J Nanomedicine; 2012; 7():1475-87. PubMed ID: 22619507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical models and technologies to advance nanovaccine development.
    Peres C; Matos AI; Moura LIF; Acúrcio RC; Carreira B; Pozzi S; Vaskovich-Koubi D; Kleiner R; Satchi-Fainaro R; Florindo HF
    Adv Drug Deliv Rev; 2021 May; 172():148-182. PubMed ID: 33711401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.